C.D. Forbes

5.1k total citations · 1 hit paper
128 papers, 3.8k citations indexed

About

C.D. Forbes is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, C.D. Forbes has authored 128 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 31 papers in Hematology and 25 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in C.D. Forbes's work include Blood properties and coagulation (36 papers), Hemophilia Treatment and Research (16 papers) and Venous Thromboembolism Diagnosis and Management (14 papers). C.D. Forbes is often cited by papers focused on Blood properties and coagulation (36 papers), Hemophilia Treatment and Research (16 papers) and Venous Thromboembolism Diagnosis and Management (14 papers). C.D. Forbes collaborates with scholars based in United Kingdom, United States and Kenya. C.D. Forbes's co-authors include Gordon Lowe, G.D.O. Lowe, J.C. Barbenel, J. J. F. Belch, C. R. M. Prentice, M. M. Drummond, C. R. M. Prentice, G.D.O. Lowe, James J. Walker and Ian A. Greer and has published in prestigious journals such as Nature, The Lancet and JAMA.

In The Last Decade

C.D. Forbes

124 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

1997 1.0k citations C.D. Forbes profile →

Peers

Countries citing papers authored by C.D. Forbes

Since Specialization

Citations

This map shows the geographic impact of C.D. Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.D. Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.D. Forbes more than expected).

Fields of papers citing papers by C.D. Forbes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.D. Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.D. Forbes. The network helps show where C.D. Forbes may publish in the future.

Co-authorship network of co-authors of C.D. Forbes

This figure shows the co-authorship network connecting the top 25 collaborators of C.D. Forbes. A scholar is included among the top collaborators of C.D. Forbes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.D. Forbes. C.D. Forbes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer-associated conditions 2024 ·Clinical & Experimental Immunology ·(unknown), A.A. van Vliet, C.D. Forbes, (unknown), (unknown), Jurriaan B. Tuynman, Hans van Vliet, Jan Spanholtz, Tanja D. de Gruijl	4
2	Disorders of the spleen 1994 ·A. Cuschieri, C.D. Forbes	2
3	Colour atlas and text of clinical medicine 1993 ·C.D. Forbes, William D. Jackson	0
4	Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. 1992 ·BMJ ·Ian A. Greer, Graham Cooke, E. Dewar, M. Blair Evans, C.D. Forbes, (unknown), J H Scurr, Michael de Swiet, London London, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	326
5	A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease 1988 ·Clinical Rheumatology ·G T Sunderland, J. J. F. Belch, R D Sturrock, C.D. Forbes, Andrew McKay	18
6	Whole blood white cell aggregation: a novel technique 1987 ·Thrombosis Research ·J. J. F. Belch, Abby R. Saniabadi, C.D. Forbes	5
7	Haematuria in patients with haemostatic defects. 1985 ·BMJ ·Ian A. Greer, G.D.O. Lowe, (unknown), (unknown), C.D. Forbes	1
8	Serum Oestradiol and Ischaemic Heart Disease - Relationship with Myocardial Infarction but not Coronary Atheroma or Haemostasis 1985 ·QJM ·Michael Small, G.D.O. Lowe, G. H. Beastall, (unknown), (unknown), I. Hutton, A R Lorimer, C.D. Forbes	28
9	The effects of intravenous ZK36-374, a stable prostacyclin analogue, on normal volunteers 1984 ·Prostaglandins & Other Lipid Mediators ·J. J. F. Belch, Ian A. Greer, M. McLaren, (unknown), Sharon Miller, R D Sturrock, C.D. Forbes	12
10	Blood Coagulation and Platelet Function following Maximal Exercise: Effects of Beta-Adrenoceptor Blockade 1984 ·Pathophysiology of Haemostasis and Thrombosis ·Michael Small, A. C. Tweddel, Andrew Rankin, G.D.O. Lowe, C. R. M. Prentice, C.D. Forbes	31
11	Effect of Prostacyclin (Epoprostenol) on the Aggregation of Human Platelets in Whole Blood in vitro 1984 ·Pathophysiology of Haemostasis and Thrombosis ·(unknown), Gordon Lowe, J. J. F. Belch, J.C. Barbenel, C.D. Forbes	15
12	Immunological abnormalities in haemophilia: are they caused by American factor VIII concentrate? 1983 ·BMJ ·(unknown), Rajan Madhok, C.D. Forbes, S E Lennie, Gordon Lowe, R D Sturrock	40
13	Diagnosis and treatment of venous thromboembolism by consultants in Scotland. 1982 ·BMJ ·Archie Prentice, G.D.O. Lowe, C.D. Forbes	18
14	Improving prospects for employment of the haemophiliac. 1980 ·BMJ ·(unknown), C.D. Forbes, (unknown), Geoffrey J. Lane, C. R. Rizza, Sally R. Wilkes	8
15	Relation between extent of coronary artery disease and blood viscosity. 1980 ·BMJ ·Gordon Lowe, M. M. Drummond, A R Lorimer, I. Hutton, C.D. Forbes, C. R. M. Prentice, J.C. Barbenel	219
16	Soluble Fibrinogen-Fibrin Complexes in Obstetrical Conditions 1977 ·Thrombosis and Haemostasis ·(unknown), (unknown), C.D. Forbes, C. R. M. Prentice	2
17	Thromboembolic Prophylaxis and Viscosity Reduction with Ancrod 1977 ·Thrombosis and Haemostasis ·G.D.O. Lowe, C.D. Forbes, C. R. M. Prentice, J.C. Barbenel	3
18	Mandril-grown graft for vascular access in Christmas disease. 1976 ·BMJ ·A.J.P. Yates, (unknown), Gerry Lowe, C.D. Forbes, C. R. M. Prentice, D. N. H. Hamilton	3
19	Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. 1976 ·BMJ ·G.D.O. Lowe, (unknown), C.D. Forbes, C. R. M. Prentice	12
20	Effect of gaboon viper ( Bitis gabonica ) venom on blood coagulation, platelets, and the fibrinolytic enzyme system 1969 ·Journal of Clinical Pathology ·C.D. Forbes, A. G. G. Turpie, Jenny Ferguson, G. P. McNicol, A. S. Douglas	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact